MARCHÉ DES MÉDICAMENTS À INSULINE HUMAINE – CROISSANCE, TENDANCES, IMPACT DU COVID-19 et prévisions (2023-2028)

Le marché est segmenté par type de produit (insulines humaines traditionnelles, insulines basales ou à action prolongée, bolus ou insulines à action rapide, combinaisons d'insuline et insulines biosimilaires) et par géographie.

Aperçu du marché

Human Insulin Drugs Market Overview
Study Period: 2016-2027
Fastest Growing Market: North America
Largest Market: North America
CAGR: 4.19 %

Major Players

Human Insulin Drugs Market Key Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Aperçu du marché

Le marché des médicaments à base d'insuline humaine devrait enregistrer un TCAC de 4,19 % au cours de la période de prévision 2020-2025 et devrait atteindre 29,9 milliards USD d'ici 2025. Le diabète est généralement considéré comme une maladie liée au mode de vie. Au fil du temps, l'incidence de la maladie a augmenté de façon scandaleuse, avec l'augmentation de la population dans le monde. Environ 100 millions de personnes dans le monde ont besoin d'insuline, y compris toutes les personnes atteintes de diabète de type 1 et entre 10 et 25 % des personnes atteintes de diabète de type 2. Bien que l'insuline soit utilisée dans le traitement du diabète depuis plus de 90 ans, à l'échelle mondiale, plus de la moitié des personnes qui en ont besoin aujourd'hui n'ont toujours pas les moyens d'en acheter et d'y accéder. Les personnes atteintes de diabète de type 1 ont besoin d'une insulinothérapie, qui se concentre sur la gestion de la glycémie, ainsi que sur l'insuline, l'alimentation et le mode de vie, afin de prévenir les complications.

Portée du rapport

L'étude porte sur les aspects suivants :

By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2025)
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Toujeo (Insulin glargine)
Tresiba (Insulin degludec)
Basaglar (Insulin glargine)
Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulins (Value and Volume, 2012-2025)
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins (Value and Volume, 2012-2025)
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec/Insulin aspart)
Xultophy (Insulin degludec/Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulins (Value and Volume, 2012-2025)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Canada (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of North America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Europe
France (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Germany (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Italy (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Spain (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
United Kingdom (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Russia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Europe (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Latin America
Mexico (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Brazil (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Latin America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Asia-Pacific
Japan (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Korea (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
China (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
India (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Australia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Vietnam (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Malaysia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Indonesia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Philippines (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Thailand (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Asia-Pacific (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Iran (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Egypt (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Oman (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Middle-East and Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins

Report scope can be customized per your requirements. Click here.

Principales tendances du marché

La prévalence croissante du diabète stimule le marché

Environ 100 millions de personnes dans le monde ont besoin d'insuline, y compris toutes les personnes atteintes de diabète de type 1 et 10 à 25 % des personnes atteintes de diabète de type 2. Bien que l'insuline soit utilisée dans le traitement du diabète à travers le monde depuis plus de 90 ans, plus de la moitié de la population qui en a besoin aujourd'hui n'en a toujours pas les moyens ou n'y a pas accès. Les personnes atteintes de diabète de type 1 ont besoin d'une insulinothérapie, et le traitement se concentre sur la gestion de la glycémie avec l'insuline, l'alimentation et le mode de vie, afin de prévenir les complications. La R&D dans les segments de l'insuline augmente d'année en année, alors que les chercheurs tentent de faire émerger la meilleure molécule pour l'usage des patients, en limitant au maximum les effets secondaires et en augmentant leur efficacité. Ainsi, la prévalence croissante de l'obésité et du diabète dans le monde est susceptible d'augmenter considérablement la demande d'insuline,

Human Insulin Drugs Market Key Trends

L'Amérique du Nord domine le marché

L'Amérique du Nord domine le marché mondial de l'insuline humaine, en particulier les États-Unis, en raison de la forte prévalence du diabète dans la région en raison d'un mode de vie sédentaire. Le facteur coût est la principale préoccupation aux États-Unis, où près de 50 % des revenus de l'insuline pour les fabricants proviennent du pays lui-même. Les États-Unis représentent les ventes les plus élevées de l'insuline à action prolongée, Lantus, à travers le monde. La majorité des fabricants de médicaments contre le diabète considèrent le pays comme un marché essentiel pour améliorer les ventes mondiales globales. Lantus est l'insuline basale la plus administrée dans le monde, représentant une part dominante sur le marché américain. Le marché nord-américain traditionnel des médicaments à base d'insuline humaine devrait croître au cours de la période de prévision, en raison de son abordabilité économique pour les patients. Humulin détient la part de marché la plus élevée, suivi de Novolin. Il n'y a pas de concurrents génériques sur le marché nord-américain traditionnel des médicaments à base d'insuline humaine aux États-Unis.

Human Insulin Drugs Market Growth by Region

Paysage concurrentiel

Le marché mondial de l'insuline humaine est fortement consolidé avec trois grands fabricants détenant une présence sur le marché mondial, et les fabricants restants se limitant aux autres fabricants locaux ou spécifiques à une région. Les fusions et acquisitions qui se sont produites entre les acteurs dans un passé récent ont aidé les entreprises à renforcer leur présence sur le marché. Eli Lilly et Boehringer Ingelheim se sont alliés pour développer et commercialiser Basaglar (Insuline Glargine).

Insulines en développement :

Novo Nordisk développe une première insuline à action prolongée une fois par semaine (LAI287) qui est actuellement en phase 2. L'insuline est indiquée pour les patients diabétiques de type 1 et de type 2. Eli Lilly développe une insuline-Fc à action prolongée (LY3209590) . "L'insuline basale-Fc" est une grande molécule composée d'insuline artificielle fusionnée à un domaine Fc conçu pour fournir un profil basal à longue durée d'action. LY3209590 est à l'étude pour le traitement du diabète.

Oral Insuline's Drugs va booster le marché :

Biocon développe Insulin Tregopil , un comprimé d'insuline prandiale orale, pour le traitement du diabète de type 1 et de type 2. L'insuline orale à action rapide pourrait améliorer le contrôle glycémique post-prandial avec des effets secondaires réduits et une plus grande observance, tenant ainsi la promesse de transformer la prise en charge du DT1. Oramed Pharmaceuticals Inc., une société pharmaceutique en phase clinique, axée sur le développement de systèmes d'administration de médicaments par voie orale, s'efforce de commercialiser le premier produit d'insuline par voie orale, offrant ainsi une méthode plus pratique, efficace et plus sûre pour délivrer une insulinothérapie.

Principaux acteurs

  1. Novo Nordisk A/S

  2. Eli Lilly and Company

  3. Sanofi S.A.

  4. Biocon Limited

  5. Pfizer Inc.

*Disclaimer: Major Players sorted in no particular order

Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company,  Biocon Limited,  Pfizer Inc., Wockhardt  Julphar, Exir, Sedico,

LIST OF TABLES AND FIGURES

 

LIST OF TABLES

1 Global Human Insulin Drugs Market: Revenue in USD million, by Product Type, 2012 - 2024
2 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
3 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
4 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Geography, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by North America, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, by United States, by Segmentation, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, by Canada, by Segmentation, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of North America, by Segmentation, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, by Europe, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, by United Kingdom, by Segmentation, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, by Germany, by Segmentation, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, by France, by Segmentation, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, by Italy, by Segmentation, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, by Spain, by Segmentation, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, by Russia, by Segmentation, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Europe, by Segmentation, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, by Latin America, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, by Mexico, by Segmentation, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, by Brazil, by Segmentation, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Latin America, by Segmentation, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, by Asia-Pacific, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, by Japan, by Segmentation, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, by South Korea, by Segmentation, 2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, by China, by Segmentation, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, by India, by Segmentation, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, by Australia, by Segmentation, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, by Vietnam, by Segmentation, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, by Malaysia, by Segmentation, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, by Indonesia, by Segmentation, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, by Philippines, by Segmentation, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, by Thailand, by Segmentation, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Asia-Pacific, by Segmentation, 2012-2024
36 Global Human Insulin Drugs Market: Revenue in USD million, by Middle East and Africa, 2012-2024
37 Global Human Insulin Drugs Market: Revenue in USD million, by Saudi Arabia, by Segmentation, 2012-2024
38 Global Human Insulin Drugs Market: Revenue in USD million, by Iran, by Segmentation, 2012-2024
39 Global Human Insulin Drugs Market: Revenue in USD million, by Egypt, by Segmentation, 2012-2024
40 Global Human Insulin Drugs Market: Revenue in USD million, by Oman, by Segmentation, 2012-2024
41 Global Human Insulin Drugs Market: Revenue in USD million, by South Africa, by Segmentation, 2012-2024
42 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Middle and Africa, by Segmentation, 2012-2024
43 Global Human Insulin Drugs Market: Revenue in USD million, by Market Indicators, 2012-2024

 

LIST OF FIGURES

1 Global Human Insulin Drugs Market, Revenue in USD million, 2012-2024
2 Global Countries Diabetes Population 2012-2024
3 Global Countries with High Obese Population, 2018
4 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, United States, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, Canada, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, Rest of North America, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, United Kingdom, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, Germany, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, France, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, Italy, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, Spain, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, Russia, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Europe, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, Japan, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, South Korea, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, China, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, India, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, Australia, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, Vietnam, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, Malaysia, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, Indonesia,  2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, Philippines, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, Thailand, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Asia-Pacific, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, Saudi Arabia, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, Iran, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, Egypt, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, Oman, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, South Africa, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Middle and Africa, 2012-2024
36 Novo Nordisk AS Diabetes Care Revenue in USD million, 2016-2018
37 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Division (2018)
38 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Geographic Segment (2018)
39 Sanofi Aventis Revenue in USD million, 2016-2018
40 Sanofi Aventis Revenue Breakdown -  By Division (2018)
41 Sanofi Aventis Revenue Breakdown -  By Geographic Segment (2018)
42 Eli Lilly Revenue in USD million, 2016-2018
43 Eli Lilly Revenue Breakdown -  By Division (2018)
44 Eli Lilly Revenue Breakdown -  By Geographic Segment (2018)
45 Biocon Revenue in USD million, 2016-2018
46 Biocon Revenue Breakdown -  By Division (2018)
47 Biocon Revenue Breakdown -  By Geographic Segment (2018)
48 Pfizer Revenue in USD million, 2016-2018
49 Pfizer Revenue Breakdown -  By Division (2018)
50 Pfizer Revenue Breakdown -  By Geographic Segment (2018)
51 Julphar Revenue in USD million, 2016-2018
52 Julphar Revenue Breakdown -  By Division (2018)
53 Julphar Revenue Breakdown -  By Geographic Segment (2018)
54 Exir Revenue in USD million, 2016-2018
55 Exir Revenue Breakdown -  By Division (2018)
56 Exir Revenue Breakdown -  By Geographic Segment (2018)
57 Sedico Revenue in USD million, 2016-2018
58 Sedico Revenue Breakdown -  By Division (2018)
59 Sedico Revenue Breakdown -  By Geographic Segment (2018)
60 Wockhardt Revenue in USD million, 2016-2018
61 Wockhardt Revenue Breakdown -  By Division (2018)
62 Wockhardt Revenue Breakdown -  By Geographic Segment (2018)
63 Company Share Analysis (2018)

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Toujeo (Insulin glargine)

        4. 5.1.1.4 Tresiba (Insulin degludec)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012-2025)

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

        1. 5.1.5.1 Insulin Glargine Biosimilars

        2. 5.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Combination Insulins

          5. 5.2.1.1.5 Biosimilar Insulins

        2. 5.2.1.2 Canada (Value and Volume, 2012-2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Combination Insulins

          5. 5.2.1.2.5 Biosimilar Insulins

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Combination Insulins

          5. 5.2.1.3.5 Biosimilar Insulins

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2025)

          1. 5.2.2.1.1 Basal or Long-acting Insulins

          2. 5.2.2.1.2 Bolus or Fast-acting Insulins

          3. 5.2.2.1.3 Traditional Human Insulins

          4. 5.2.2.1.4 Combination Insulins

          5. 5.2.2.1.5 Biosimilar Insulins

        2. 5.2.2.2 Germany (Value and Volume, 2012-2025)

          1. 5.2.2.2.1 Basal or Long-acting Insulins

          2. 5.2.2.2.2 Bolus or Fast-acting Insulins

          3. 5.2.2.2.3 Traditional Human Insulins

          4. 5.2.2.2.4 Combination Insulins

          5. 5.2.2.2.5 Biosimilar Insulins

        3. 5.2.2.3 Italy (Value and Volume, 2012-2025)

          1. 5.2.2.3.1 Basal or Long-acting Insulins

          2. 5.2.2.3.2 Bolus or Fast-acting Insulins

          3. 5.2.2.3.3 Traditional Human Insulins

          4. 5.2.2.3.4 Combination Insulins

          5. 5.2.2.3.5 Biosimilar Insulins

        4. 5.2.2.4 Spain (Value and Volume, 2012-2025)

          1. 5.2.2.4.1 Basal or Long-acting Insulins

          2. 5.2.2.4.2 Bolus or Fast-acting Insulins

          3. 5.2.2.4.3 Traditional Human Insulins

          4. 5.2.2.4.4 Combination Insulins

          5. 5.2.2.4.5 Biosimilar Insulins

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)

          1. 5.2.2.5.1 Basal or Long-acting Insulins

          2. 5.2.2.5.2 Bolus or Fast-acting Insulins

          3. 5.2.2.5.3 Traditional Human Insulins

          4. 5.2.2.5.4 Combination Insulins

          5. 5.2.2.5.5 Biosimilar Insulins

        6. 5.2.2.6 Russia (Value and Volume, 2012-2025)

          1. 5.2.2.6.1 Basal or Long-acting Insulins

          2. 5.2.2.6.2 Bolus or Fast-acting Insulins

          3. 5.2.2.6.3 Traditional Human Insulins

          4. 5.2.2.6.4 Combination Insulins

          5. 5.2.2.6.5 Biosimilar Insulins

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)

          1. 5.2.2.7.1 Basal or Long-acting Insulins

          2. 5.2.2.7.2 Bolus or Fast-acting Insulins

          3. 5.2.2.7.3 Traditional Human Insulins

          4. 5.2.2.7.4 Combination Insulins

          5. 5.2.2.7.5 Biosimilar Insulins

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2025)

          1. 5.2.3.1.1 Basal or Long-acting Insulins

          2. 5.2.3.1.2 Bolus or Fast-acting Insulins

          3. 5.2.3.1.3 Traditional Human Insulins

          4. 5.2.3.1.4 Combination Insulins

          5. 5.2.3.1.5 Biosimilar Insulins

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2025)

          1. 5.2.3.2.1 Basal or Long-acting Insulins

          2. 5.2.3.2.2 Bolus or Fast-acting Insulins

          3. 5.2.3.2.3 Traditional Human Insulins

          4. 5.2.3.2.4 Combination Insulins

          5. 5.2.3.2.5 Biosimilar Insulins

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)

          1. 5.2.3.3.1 Basal or Long-acting Insulins

          2. 5.2.3.3.2 Bolus or Fast-acting Insulins

          3. 5.2.3.3.3 Traditional Human Insulins

          4. 5.2.3.3.4 Combination Insulins

          5. 5.2.3.3.5 Biosimilar Insulins

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2025)

          1. 5.2.4.1.1 Basal or Long-acting Insulins

          2. 5.2.4.1.2 Bolus or Fast-acting Insulins

          3. 5.2.4.1.3 Traditional Human Insulins

          4. 5.2.4.1.4 Combination Insulins

          5. 5.2.4.1.5 Biosimilar Insulins

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2025)

          1. 5.2.4.2.1 Basal or Long-acting Insulins

          2. 5.2.4.2.2 Bolus or Fast-acting Insulins

          3. 5.2.4.2.3 Traditional Human Insulins

          4. 5.2.4.2.4 Combination Insulins

          5. 5.2.4.2.5 Biosimilar Insulins

        3. 5.2.4.3 China (Value and Volume, 2012-2025)

          1. 5.2.4.3.1 Basal or Long-acting Insulins

          2. 5.2.4.3.2 Bolus or Fast-acting Insulins

          3. 5.2.4.3.3 Traditional Human Insulins

          4. 5.2.4.3.4 Combination Insulins

          5. 5.2.4.3.5 Biosimilar Insulins

        4. 5.2.4.4 India (Value and Volume, 2012-2025)

          1. 5.2.4.4.1 Basal or Long-acting Insulins

          2. 5.2.4.4.2 Bolus or Fast-acting Insulins

          3. 5.2.4.4.3 Traditional Human Insulins

          4. 5.2.4.4.4 Combination Insulins

          5. 5.2.4.4.5 Biosimilar Insulins

        5. 5.2.4.5 Australia (Value and Volume, 2012-2025)

          1. 5.2.4.5.1 Basal or Long-acting Insulins

          2. 5.2.4.5.2 Bolus or Fast-acting Insulins

          3. 5.2.4.5.3 Traditional Human Insulins

          4. 5.2.4.5.4 Combination Insulins

          5. 5.2.4.5.5 Biosimilar Insulins

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2025)

          1. 5.2.4.6.1 Basal or Long-acting Insulins

          2. 5.2.4.6.2 Bolus or Fast-acting Insulins

          3. 5.2.4.6.3 Traditional Human Insulins

          4. 5.2.4.6.4 Combination Insulins

          5. 5.2.4.6.5 Biosimilar Insulins

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2025)

          1. 5.2.4.7.1 Basal or Long-acting Insulins

          2. 5.2.4.7.2 Bolus or Fast-acting Insulins

          3. 5.2.4.7.3 Traditional Human Insulins

          4. 5.2.4.7.4 Combination Insulins

          5. 5.2.4.7.5 Biosimilar Insulins

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2025)

          1. 5.2.4.8.1 Basal or Long-acting Insulins

          2. 5.2.4.8.2 Bolus or Fast-acting Insulins

          3. 5.2.4.8.3 Traditional Human Insulins

          4. 5.2.4.8.4 Combination Insulins

          5. 5.2.4.8.5 Biosimilar Insulins

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2025)

          1. 5.2.4.9.1 Basal or Long-acting Insulins

          2. 5.2.4.9.2 Bolus or Fast-acting Insulins

          3. 5.2.4.9.3 Traditional Human Insulins

          4. 5.2.4.9.4 Combination Insulins

          5. 5.2.4.9.5 Biosimilar Insulins

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2025)

          1. 5.2.4.10.1 Basal or Long-acting Insulins

          2. 5.2.4.10.2 Bolus or Fast-acting Insulins

          3. 5.2.4.10.3 Traditional Human Insulins

          4. 5.2.4.10.4 Combination Insulins

          5. 5.2.4.10.5 Biosimilar Insulins

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)

          1. 5.2.4.11.1 Basal or Long-acting Insulins

          2. 5.2.4.11.2 Bolus or Fast-acting Insulins

          3. 5.2.4.11.3 Traditional Human Insulins

          4. 5.2.4.11.4 Combination Insulins

          5. 5.2.4.11.5 Biosimilar Insulins

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)

          1. 5.2.5.1.1 Basal or Long-acting Insulins

          2. 5.2.5.1.2 Bolus or Fast-acting Insulins

          3. 5.2.5.1.3 Traditional Human Insulins

          4. 5.2.5.1.4 Combination Insulins

          5. 5.2.5.1.5 Biosimilar Insulins

        2. 5.2.5.2 Iran (Value and Volume, 2012-2025)

          1. 5.2.5.2.1 Basal or Long-acting Insulins

          2. 5.2.5.2.2 Bolus or Fast-acting Insulins

          3. 5.2.5.2.3 Traditional Human Insulins

          4. 5.2.5.2.4 Combination Insulins

          5. 5.2.5.2.5 Biosimilar Insulins

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2025)

          1. 5.2.5.3.1 Basal or Long-acting Insulins

          2. 5.2.5.3.2 Bolus or Fast-acting Insulins

          3. 5.2.5.3.3 Traditional Human Insulins

          4. 5.2.5.3.4 Combination Insulins

          5. 5.2.5.3.5 Biosimilar Insulins

        4. 5.2.5.4 Oman (Value and Volume, 2012-2025)

          1. 5.2.5.4.1 Basal or Long-acting Insulins

          2. 5.2.5.4.2 Bolus or Fast-acting Insulins

          3. 5.2.5.4.3 Traditional Human Insulins

          4. 5.2.5.4.4 Combination Insulins

          5. 5.2.5.4.5 Biosimilar Insulins

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2025)

          1. 5.2.5.5.1 Basal or Long-acting Insulins

          2. 5.2.5.5.2 Bolus or Fast-acting Insulins

          3. 5.2.5.5.3 Traditional Human Insulins

          4. 5.2.5.5.4 Combination Insulins

          5. 5.2.5.5.5 Biosimilar Insulins

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)

          1. 5.2.5.6.1 Basal or Long-acting Insulins

          2. 5.2.5.6.2 Bolus or Fast-acting Insulins

          3. 5.2.5.6.3 Traditional Human Insulins

          4. 5.2.5.6.4 Combination Insulins

          5. 5.2.5.6.5 Biosimilar Insulins

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (5 Years)

        5. 7.1.1.5 Strength and Stability Analysis (5 Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (5 Years)

        5. 7.1.2.5 Strength and Stability Analysis (5 Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (5 Years)

        5. 7.1.3.5 Strength and Stability Analysis (5 Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (5 Years)

        5. 7.1.4.5 Strength and Stability Analysis (5 Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (5 Years)

        5. 7.1.5.5 Strength and Stability Analysis (5 Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (5 Years)

        5. 7.1.6.5 Strength and Stability Analysis (5 Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

Le marché des médicaments à base d’insuline humaine est étudié de 2018 à 2028.

Le marché des médicaments à base d'insuline humaine croît à un TCAC> 3% au cours des 5 prochaines années.

Le marché des médicaments à base d'insuline humaine est évalué à 26 milliards de dollars en 2018.

Le marché des médicaments à base d'insuline humaine est évalué à 32 milliards de dollars en 2028.

L'Amérique du Nord affiche le TCAC le plus élevé de 2018 à 2028.

L'Amérique du Nord détient la part la plus élevée en 2021.

Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited, Pfizer Inc. sont les principales sociétés opérant sur le marché des médicaments à base d'insuline humaine.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!